ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025
Association of a mild or an important decline in left ventricular ejection fraction with ventricular tachyarrhythmias, sudden cardiac death, and all-cause death in heart failure with preserved ejection fraction: a report from the CHART-2 Study.
Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00418041 (Chronic Heart Failure Analysis and Registry in the Tohoku District 2), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimsA decline in left ventricular ejection fraction (LVEF) is often observed in patients with heart failure with preserved ejection fraction (HFpEF) and is associated with adverse outcomes. Although baseline LVEF is crucial for assessing the risk of sudden cardiac death in patients with HF, little is known about the relationship between the decline in LVEF and lethal arrhythmic events among patients with HFpEF. METHODS AND
resultsWe retrospectively analysed data from the CHART-2 Study. A total of 1453 patients with HF and LVEF ≥ 50% at registration (73 years, 39% female) were included and categorized into three groups based on their LVEF at the prespecified 1-year follow-up; 1316 with LVEF ≥ 50%, 120 with LVEF 36-50%, and 17 with LVEF ≤ 35%. The primary endpoint was a composite of ventricular tachycardia, ventricular fibrillation, and sudden cardiac death. All-cause death was also evaluated. During a median follow-up of 7.9 years, 79 (5.4%) patients experienced a composite event. Patients with LVEF < 50% at 1 year had a significantly higher incidence of the composite event (11.7 vs. 4.8%, P < 0.001), and all-cause death (62.8% vs. 51.8%, P = 0.006), compared to those with LVEF ≥ 50%. Importantly, a decline in LVEF to <50% was independently associated with an increased risk of the composite event (adjusted hazard ratio 1.99, 95% CI 1.04-3.79, P = 0.04).
conclusionIn patients with HFpEF, even a mild decline in LVEF was associated with a higher risk of ventricular tachyarrhythmia, sudden cardiac death, and all-cause death. Continuous clinical assessment and re-evaluation of LVEF is crucial for the management of patients with HFpEF. CLINICAL
trial registrationhttps://www.clinicaltrials.gov; unique identifier: NCT00418041.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.